C/EBPβ Helps MYB Maintain the Oncogenic Program of AML Cells

BUFFALO, NY- November 13, 2023 – A new #editorial perspective was #published in Oncotarget's Volume 14 on March 11, 2023, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.” In this new paper, researcher Karl-Heinz Klempnauer from Westfälische-Wilhelms-Universität discusses recent studies on the role of transcription factor MYB in acute myeloid leukemia (AML). MYB has been identified as a key regulator of a transcriptional program for self-renewal of AML cells. The MYB gene initially attracted attention as the progenitor of a retrovirally-transduced oncogene that induces a myeloid leukemia in chicken [1–4]. MYB encodes a transcription factor with essential roles in the development of the hematopoietic system [5] and the proliferation and differentiation of hematopoietic progenitor cells [6]. Subsequent work identified MYB also as a crucial player in the development and maintenance of leukemia in humans. “Recent work summarized here has now highlighted the CCAAT-box/enhancer binding protein beta (C/EBPβ) as an essential factor and potential therapeutic target that cooperates with MYB and coactivator p300 in the maintenance of the leukemic cells.” DOI - https://doi.org/10.18632/oncotarget.28377 Correspondence to - Karl-Heinz Klempnauer - klempna@uni-muenster.de Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28377 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, MYB, C/EBPbeta, p300, GFI1, AML About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957